Literature DB >> 14872024

Higher atrophy rate of entorhinal cortex than hippocampus in AD.

A T Du1, N Schuff, J H Kramer, S Ganzer, X P Zhu, W J Jagust, B L Miller, B R Reed, D Mungas, K Yaffe, H C Chui, M W Weiner.   

Abstract

OBJECTIVES: To determine if atrophy rates were higher for entorhinal cortex (ERC) than for hippocampus in Alzheimer disease (AD), to determine the relationship between hippocampal atrophy rate and memory impairment, and to compare atrophy rates of ERC and hippocampus in differentiating between patients with AD and cognitively normal (CN) controls.
METHODS: Twenty patients with AD and 25 CN subjects had MRI scans and clinical evaluations twice approximately 1.9 years apart. ERC volumes were measured manually and hippocampal volumes were measured semiautomatically on volumetric T1-weighted MR images.
RESULTS: In AD, the atrophy rate of ERC (7.1 +/- 3.2%/year) was higher (p < 0.02) than that of hippocampus (5.9 +/- 2.4%/year). Furthermore, memory deficit in mild AD, measured with the Delayed List Verbal Recall test, correlated significantly with atrophy rates of both ERC (r = -0.61) and hippocampus (r = -0.59). Atrophy rates of ERC and hippocampus were comparable in differentiating between AD and CN. Using atrophy rates of ERC or hippocampus to detect a 20% treatment effect with 90% power (p < 0.05) would require about 100 completed patients per arm in a 2-year study.
CONCLUSION: The finding in AD that the atrophy rate in the entorhinal cortex is higher than in the hippocampus is consistent with the view that AD pathology begins in the entorhinal cortex.

Entities:  

Mesh:

Year:  2004        PMID: 14872024      PMCID: PMC1820859          DOI: 10.1212/01.wnl.0000106462.72282.90

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  34 in total

1.  Unbiased whole-brain analysis of gray matter loss in Alzheimer's disease.

Authors:  S A Rombouts; F Barkhof; M P Witter; P Scheltens
Journal:  Neurosci Lett       Date:  2000-05-19       Impact factor: 3.046

2.  Reliability of tissue volumes and their spatial distribution for segmented magnetic resonance images.

Authors:  V A Cardenas; F Ezekiel; V Di Sclafani; B Gomberg; G Fein
Journal:  Psychiatry Res       Date:  2001-05-30       Impact factor: 3.222

3.  Progression of corpus callosum atrophy in Alzheimer disease.

Authors:  Stefan J Teipel; Wolfram Bayer; Gene E Alexander; York Zebuhr; Diane Teichberg; Luka Kulic; Marc B Schapiro; Hans-Jürgen Möller; Stanley I Rapoport; Harald Hampel
Journal:  Arch Neurol       Date:  2002-02

4.  Usefulness of MRI measures of entorhinal cortex versus hippocampus in AD.

Authors:  Y Xu; C R Jack; P C O'Brien; E Kokmen; G E Smith; R J Ivnik; B F Boeve; R G Tangalos; R C Petersen
Journal:  Neurology       Date:  2000-05-09       Impact factor: 9.910

5.  Rates of global and regional cerebral atrophy in AD and frontotemporal dementia.

Authors:  D Chan; N C Fox; R Jenkins; R I Scahill; W R Crum; M N Rossor
Journal:  Neurology       Date:  2001-11-27       Impact factor: 9.910

6.  Rates of hippocampal atrophy correlate with change in clinical status in aging and AD.

Authors:  C R Jack; R C Petersen; Y Xu; P C O'Brien; G E Smith; R J Ivnik; B F Boeve; E G Tangalos; E Kokmen
Journal:  Neurology       Date:  2000-08-22       Impact factor: 9.910

7.  Magnetic resonance imaging of the entorhinal cortex and hippocampus in mild cognitive impairment and Alzheimer's disease.

Authors:  A T Du; N Schuff; D Amend; M P Laakso; Y Y Hsu; W J Jagust; K Yaffe; J H Kramer; B Reed; D Norman; H C Chui; M W Weiner
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-10       Impact factor: 10.154

8.  Cortical change in Alzheimer's disease detected with a disease-specific population-based brain atlas.

Authors:  P M Thompson; M S Mega; R P Woods; C I Zoumalan; C J Lindshield; R E Blanton; J Moussai; C J Holmes; J L Cummings; A W Toga
Journal:  Cereb Cortex       Date:  2001-01       Impact factor: 5.357

9.  Measuring cognitive change in a cohort of patients with Alzheimer's disease.

Authors:  D R Galasko; R L Gould; I S Abramson; D P Salmon
Journal:  Stat Med       Date:  2000 Jun 15-30       Impact factor: 2.373

10.  MRI-derived entorhinal and hippocampal atrophy in incipient and very mild Alzheimer's disease.

Authors:  B C Dickerson; I Goncharova; M P Sullivan; C Forchetti; R S Wilson; D A Bennett; L A Beckett; L deToledo-Morrell
Journal:  Neurobiol Aging       Date:  2001 Sep-Oct       Impact factor: 4.673

View more
  69 in total

1.  Longitudinal changes in cortical thickness associated with normal aging.

Authors:  Madhav Thambisetty; Jing Wan; Aaron Carass; Yang An; Jerry L Prince; Susan M Resnick
Journal:  Neuroimage       Date:  2010-05-02       Impact factor: 6.556

2.  Selective interaction of lansoprazole and astemizole with tau polymers: potential new clinical use in diagnosis of Alzheimer's disease.

Authors:  Leonel E Rojo; Jans Alzate-Morales; Iván N Saavedra; Peter Davies; Ricardo B Maccioni
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

3.  Measuring longitudinal change in the hippocampal formation from in vivo high-resolution T2-weighted MRI.

Authors:  Sandhitsu R Das; Brian B Avants; John Pluta; Hongzhi Wang; Jung W Suh; Michael W Weiner; Susanne G Mueller; Paul A Yushkevich
Journal:  Neuroimage       Date:  2012-01-28       Impact factor: 6.556

4.  Abnormalities of hippocampal surface structure in very mild dementia of the Alzheimer type.

Authors:  Lei Wang; J Philp Miller; Mokhtar H Gado; Daniel W McKeel; Marcus Rothermich; Michael I Miller; John C Morris; John G Csernansky
Journal:  Neuroimage       Date:  2005-10-21       Impact factor: 6.556

Review 5.  Positron emission tomography and single-photon emission computed tomography in central nervous system drug development.

Authors:  David J Brooks
Journal:  NeuroRx       Date:  2005-04

6.  Age effects on atrophy rates of entorhinal cortex and hippocampus.

Authors:  An-Tao Du; Norbert Schuff; Linda L Chao; John Kornak; William J Jagust; Joel H Kramer; Bruce R Reed; Bruce L Miller; David Norman; Helena C Chui; Michael W Weiner
Journal:  Neurobiol Aging       Date:  2005-06-14       Impact factor: 4.673

Review 7.  The role of biomarkers in clinical trials for Alzheimer disease.

Authors:  Leon J Thal; Kejal Kantarci; Eric M Reiman; William E Klunk; Michael W Weiner; Henrik Zetterberg; Douglas Galasko; Domenico Praticò; Sue Griffin; Dale Schenk; Eric Siemers
Journal:  Alzheimer Dis Assoc Disord       Date:  2006 Jan-Mar       Impact factor: 2.703

8.  Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease.

Authors:  John C Morris; Catherine M Roe; Elizabeth A Grant; Denise Head; Martha Storandt; Alison M Goate; Anne M Fagan; David M Holtzman; Mark A Mintun
Journal:  Arch Neurol       Date:  2009-12

9.  Ways toward an early diagnosis in Alzheimer's disease: the Alzheimer's Disease Neuroimaging Initiative (ADNI).

Authors:  Susanne G Mueller; Michael W Weiner; Leon J Thal; Ronald C Petersen; Clifford R Jack; William Jagust; John Q Trojanowski; Arthur W Toga; Laurel Beckett
Journal:  Alzheimers Dement       Date:  2005-07       Impact factor: 21.566

10.  CSF biomarkers in frontotemporal lobar degeneration with known pathology.

Authors:  H Bian; J C Van Swieten; S Leight; L Massimo; E Wood; M Forman; P Moore; I de Koning; C M Clark; S Rosso; J Trojanowski; V M-Y Lee; M Grossman
Journal:  Neurology       Date:  2008-05-06       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.